Metformin as RenoProtector of Progressive Kidney Disease
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
A multi-center, practice-oriented, repurposing, double-blinded, placebo-controlled,
randomized clinical trial. The RenoMet trial is repurposing an already approved agent
(Metformin , Glucophage SR ) in a new indication (renoprotection ) in a new class of patients
(chronic kidney disease patients CKD 2, 3A, 3B and including patients with renal transplant
for more than 3 years).